Gain Therapeutics
GANX
GANX
16 hedge funds and large institutions have $4.75M invested in Gain Therapeutics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$363K | |
| 2 | +$162K | |
| 3 | +$143K | |
| 4 |
Jane Street
New York
|
+$48K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.6K |
Top Sellers
| 1 | -$106K | |
| 2 | -$103K | |
| 3 | -$70K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$40.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$26.5K |